March 18th 2021 Chambers and Partners Europe has announced the results of its annual research of the leading legal advisors. Lidings is traditionally highly recommended for Dispute Resolution, Corporate and M&A and Life Sciences advice in Russia.  The Firm’s Intellectual Property practice has also entered the ranking this year.

Lidings demonstrates new achievements and takes advanced positions in the rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. Results of the new research published in a special supplement to Kommersant as of March 17, 2021.

March 11, 2021 Pravo.ru-300 released its individual rating of lawyers. Based on the new rating Lidings managing partner Andrey Zelenin, partners Stepan Guzey and Alexander Popleyuk take top positions in key practice areas.

Since 1 March 2021, the Pharmaceutical Register of the Eurasian Patent Office (EAPO) is available on the official website of the Eurasian Patent Office. The Register contains information on Eurasian patents protecting active substances of drugs.

Chambers and Partners Global has announced the results of its annual research of the leading legal advisors around the world. Lidings’ is recommended among the top legal advisors in intellectual property in Russia.

The rating particularly states that Andrey is “well versed in all aspects of intellectual property and can hammer out favourable outcomes in difficult disputes in the life sciences, fast-moving consumer goods and high-technology spheres” and Boris is “a trusted adviser to numerous pharmaceutical companies on both the patent and trademark sides, and has further know-how in advertising and data protection.

Lidings’ managing partner Andrey Zelenin heading the firm’s Pharmaceuticals and Healthcare industry practice and partner Boris Malakhov, Head of the Intellectual Property practice of the firm, run a special webinar on the key market developments in the healthcare and life sciences sector in Russia.

On January 5, 2021 the Decree of the Government of the Russian Federation No. 3718-r dated December 31, 2020 (the Decree) was published. In accordance with the Decree, Pharmasintez JSC, a Russian generic company, has been granted a 1-year compulsory license to use the inventions of the US companies Gilead Sciences Inc. and Gilead Pharmasset LLC protecting Remdesivir subject to a “fair compensation”¹.